Introduction
Wilms' tumor is the second most common intra-abdominal cancer of childhood and the fifth most common pediatric malignancy overall. It represents approximately 6% of all pediatric cancers and accounts for more than 95% of all tumors of the kidney in the pediatric age group [1, 2] . In the United States, there are approximately eight cases of Wilms' tumor per million children less than 15 years of age per year, with the total number of new cases being estimated at about 500 per year [3] . Approximately 75% of the cases occur in children less than 5 years of age with a peak incidence at 2-3 years of age. Survival for patients with Wilms' tumor when considered as a whole, once less than 30%, is currently greater than 90%, making it one of the real successes of modern medicine. This dramatic improvement in survival is due, in part, to the systematic manner in which the approach to therapy has evolved. Surgery is a critical component of this therapy and the role of the surgeon is central in the treatment of these patients. However, the addition and refinement of chemotherapy, and, in certain circumstances, radiation therapy, have also had a significant impact on achieving improved survival rates. There are a number of excellent papers that provide overviews of Wilms' tumor and the current clinical management of children with this disease [4] [5] [6] [7] [8] [9] [10] [11] [12] . This review will focus on describing the results of prior clinical trials that have led to the excellent outcome for children with Wilms' tumor and how these results have led to the development of the current series of clinical trials. The current risk stratification and general treatment approaches for patients with Wilms' tumor and the critical role played by the surgeon will be highlighted.
National Wilms' tumor studies
Due to the rarity of Wilms' tumor, organized clinical investigation was limited until the establishment of the National Wilms' Tumor Study (NWTS) in 1969. This represented a cooperative effort among several groups to treat patients in a clearly defined manner, so that statistically relevant comparisons of treatment variations could be made. Five sequential trials have been completed, with the basic goal of each successive NWTS trial having been to maintain a high cure rate for patients with Wilms' tumor, while reducing the intensity and duration of therapy, based on surgical stage and histologic evaluation. Although the importance of surgery in the treatment of Wilms' tumor has long been recognized, the roles for chemotherapy and radiation therapy have evolved based on the results of the NWTS trials.
NWTS-1 showed that postoperative abdominal radiotherapy was not necessary for children who were less than 2 years of age and whose tumors were limited to the kidney and completely resected [13] . In addition, the combination of vincristine and dactinomycin was shown to be more effective for the treatment of children with tumors that extended beyond the kidney than either drug alone. NWTS-2 demonstrated that 5 months of combination chemotherapy with vincristine and dactinomycin was effective treatment for children with tumors limited to the kidney and completely resected; none of these children received abdominal radiation. The addition of adriamycin to the combination of vincristine and actinomycin D was found to improve the relapse-free survival of other patients [14] . The separation of Wilms' tumor into distinct histopathologic categories based on prognosis was used to stratify patients in NWTS-3 [15] . NWTS-4 examined the utility of dose-intensive scheduling to cut down on the duration of therapy [16] . The more recently concluded NWTS-5, a single-arm therapeutic trial designed to evaluate the prognostic value of certain biologic markers in Wilms' tumor, demonstrated that loss of heterozygosity (LOH) for genetic material on chromosomes 1p and 16q in Stages I and II favorable histology Wilms' tumor was associated with a poorer prognosis [17] . This information, loss of heterozygosity of 1p and 16q, is now being used to further stratify patients in the current Children's Oncology Group (COG) trial for Wilms' tumor.
Current protocols
Historically, the most important prognostic variables for patients with Wilms' tumor have been the histopathologic tumor classification and surgical stage [18] . Survival statistics based on these factors, which have largely guided treatment, are shown in Table 1 . The staging system developed by the NWTS and currently in common use is shown in Table 2 . Because appropriate therapy, as well as prognosis, is based on tumor stage, accurate staging of patients with Wilms' tumor at the time of diagnosis is imperative and includes histologic assessment of regional lymph node involvement. There are two distinct histopathologic types of Wilms' tumor, favorable and unfavorable [19] . The unfavorable group consists of Wilms' tumors with anaplasia (extreme nuclear and cytologic atypia). Anaplasia is present in about 5% of Wilms' tumor and is more common in older children, reaching a peak at approximately 5 years of age [20] . This histopathologic variant is also more frequent in African-American patients than in white patients. There are two additional, distinct renal tumors that can occur in children, each characterized by sarcomatous stroma and a poor outcome. They are clear cell sarcoma of the kidney and malignant rhabdoid tumor of the kidney [19] . As these are distinct from Wilms' tumor, they will not be discussed further in this review.
It has recently been recognized that a Wilms' tumor risk stratification system based on histology and stage alone does not accurately identify all patients at risk for recurrence. New clinical and genetic risk factors for recurrence have been validated and have now been incorporated into the assigning of therapy in the current COG clinical trials for patients with Wilms' tumor. These factors include patient age at the time of diagnosis, tumor weight, OS, overall survival; RFS, relapse-free survival. There is regional extension of the tumor; i.e., penetration through the outer surface of the renal capsule into perirenal soft tissues. Vessels outside the kidney substance are infiltrated or contain tumor thrombus. The tumor may have been biopsied or there has been local spillage of tumor contained to the flank. There is no residual tumor apparent at or beyond the margins of excision. III. Residual nonhematogenous tumor confined to abdomen. Any one or more of the following occur: 1. Lymph nodes on biopsy are found to be involved in the hilus, the periaortic chains or beyond. 2. There has been diffuse peritoneal contamination by tumor such as by spillage of tumor beyond the flank before or during surgery, or by tumor growth that has penetrated through the peritoneal surface. 3. Implants are found on the peritoneal surfaces. 4. The tumor extends beyond the surgical margins either microscopically or grossly. 5. The tumor is not completely resectable because of local infiltration into vital structures. IV. Hematogenous metastases. Deposits beyond Stage III; i.e., lung, liver, bone, and brain. V. Bilateral renal involvement at diagnosis. An attempt should be made to stage each side according to the above criteria on the basis of extent of disease prior to biopsy.
histologic response to therapy, and the allelic status of chromosomes 1p and 16q in resected tumors.
Since 2006, four clinical trials have opened within COG for the treatment of patients with Wilms' tumor. Together these protocols cover the entire spectrum of Wilms' tumor. Central to the approach to therapy for these patients is a risk classification scheme, which is defined in Due to an increased risk of renal failure in patients with bilateral Wilms' tumor, these patients receive neoadjuvant therapy with three-drug chemotherapy of regimen DD-4A in an effort to shrink the tumors prior to surgery and facilitate the preservation of renal parenchyma, thereby preserving renal function. Also eligible for enrollment on this protocol are patients with Wilms' tumor arising in a solitary kidney or those patients with a unilateral Wilms' tumor who are less than 1 year of age and at an increased risk for a metachronous tumor.
Patients with a number of genetic syndromes, particularly those associated with abnormalities of the Wilms' tumor 1 (WT 1) and Wilms' tumor 2 (WT 2) genes on the short arm of chromosome 11, carry this risk (see Table 4 ). Patients with unilateral Wilms' tumor and a Wilms' tumor predisposition syndrome are treated with regimen EE-4A if their disease is Stages I-II but DD-4A if the disease is Stages II-IV.
Surgery for Wilms' tumor
The role of surgery in the therapy of Wilms' tumor is paramount, as a meticulous and well performed procedure will accurately determine the stage of the patient and their future therapy. A poorly performed procedure can led to inadequate therapy if patients are not appropriately staged or to unnecessarily intensive therapy if operative spill of the tumor occurs or if incomplete resection of the primary tumor is carried out. The main responsibility of the surgeon is to remove the primary tumor completely, without spillage, and to accurately assess the extent to which the tumor has spread, with particular attention to adequately assessing lymph node involvement.
Timing of surgery
One of the main controversies in the treatment of children with Wilms' tumor is whether or not to administer preoperative chemotherapy, as suggested by the International Society of Pediatric Oncology (SIOP) [21 ,22-26] . The surgeon considering the use of preoperative chemotherapy should realize that there can be significant adverse affects on staging and histological evaluation in children who receive preoperative chemotherapy, which could led to either overtreatment or undertreatment. Evidence to support the dangers of undertreatment is a SIOP study that showed an increased incidence of infradiaphragmatic relapses in patients who did not receive postoperative radiation therapy [27] . Likely, patients with lymph node involvement were missed due to preoperative chemotherapy.
Proponents of preoperative therapy suggest that the tumor is easier to resect with a decreased incidence of tumor spill and a lower mortality and morbidity. However, the morbidity and mortality following tumor resection in NWTS are extremely low and the incidence of tumor spill is less than 10%.
Despite the arguments given above against the use of preoperative therapy, specific patient groups can be identified who would seem to benefit from preoperative chemotherapy. These are patients with bilateral tumors, Wilms' tumor Davidoff 361 those with inferior vena cava and intra-atrial involvement, and patients with massive tumors considered by the operating surgeon to be unresectable without undue risk to the patient.
Surgical exploration
A radical nephrectomy should be carried out through a generous transverse, transperitoneal incision. A thoracic extension may be necessary but has been associated with a higher complication rate [28] . Isolation of the hilar vessels prior to mobilization of the primary tumor is no longer recommended because major vascular injury to the mesenteric arteries, celiac vessels, and aorta has been reported [29] . Palpation of the renal vein prior to its division is recommended to exclude the possibility of a tumor thrombus, as occurs in about 10% of cases. Biopsy of the primary tumor should not be carried out prior to its removal, and a meticulous dissection to avoid rupture of the tumor capsule with spillage of tumor cells is imperative, as tumor spill is strongly associated with recurrence [30] . During tumor resection, the ureter is ligated and divided as low as possible, but complete removal of the ureter down to the bladder is not necessary. Intra-operative inspection of the liver and the contralateral kidney is no longer required, unless lesions had been identified on preoperative imaging studies, because of the high accuracy of current imaging modalities. However, lymph node sampling is critically important, despite the absence of abnormal nodes on preoperative imaging or upon gross inspection during operative exploration, as a review of lymph node sampling by the NWTS demonstrated a false negative rate of 31% and a false positive rate of 18% based on preoperative and intra-operative assessments [31] . Unfortunately, there is currently a fairly high incidence of inadequate intra-operative staging, primarily due to failure to sample lymph nodes [32] .
Wilms' tumors rarely invade surrounding structures but frequently adhere to adjacent organs. If the tumor cannot be cleanly separated from adjacent structures, then excision of the tumor with surrounding structures can be carried out in continuity if the operating surgeon feels that all tumor tissue can be completely removed. Because patients with small residual disease respond well to present chemotherapy and because an increased incidence of complications has been associated with tumor resections that include adjacent structures, radical resection is only indicated if all tumors can be removed. In the case of hepatic invasion, a resection of part of the liver along with the primary tumor can usually be carried out. However, a formal hepatectomy is rarely indicated.
There are reports of surgeons performing unilateral partial nephrectomy and laparoscopic nephrectomy (radical or partial) for Wilms' tumor, particularly in Europe where children routinely receive preoperative chemotherapy [33] [34] [35] [36] [37] . However, the appropriateness and adequacy of these approaches have not been confirmed and they are not currently endorsed by COG.
Very low risk favorable histology Wilms' tumor
Children less than 2 years of age with unilateral, favorable histology, Stage I tumors that weighed less than 550 g were felt to be at such low risk for recurrence that the risks of adjuvant chemotherapy might outweigh the risks of recurrence. Therefore, in NWTS-5, these patients were treated with surgery alone. However, because the 2-year event-free survival (EFS), 86.5%, did not meet the required EFS of 90%, this arm of the trial was stopped. Subsequent evaluation of the data, in which the overall survival of the patients who suffered a relapse was 91% with adjuvant therapy, higher than the expected salvage rate of 50% [38] , has renewed enthusiasm for this approach, which has been re-instituted. It should be noted that a critical component of the entry criteria is that adequate lymph node sampling be performed at the time of tumor resection to ensure accurate confirmation of Stage I disease.
Bilateral Wilms' tumor
Synchronous disease in both kidneys at presentation occurs in approximately 5% of children with Wilms' tumor. Unfavorable histology is seen in approximately 10% of the cases and there can be discordant histology. However, because tumor biopsy, regardless of the technique, is very unlikely to document anaplastic histology [39] and because there are few other things, other than Wilms' tumor, in the differential diagnosis for a child with bilateral renal masses, biopsy at presentation is now discouraged by COG.
As surgery is a critical component in the treatment of Wilms' tumor, the challenge in the management of patients with bilateral disease is to achieve a high cure rate while maintaining adequate long-term renal function. Several studies have demonstrated that patients with bilateral Wilms' tumor are at risk for developing renal failure [40] [41] [42] [43] . The exact cause of renal failure is not always clear and is likely multifactorial [41, 43] . However, because of an increasing appreciation of the potential for renal failure in these patients, the management of synchronous bilateral Wilms' tumor has evolved from primary kidney resection to renal-preserving surgical approaches, facilitated by the use of preoperative chemotherapy. We have recently reviewed our experience at St Jude Children's Research Hospital and found that we were able to perform bilateral partial nephrectomies in nearly all patients (>90%) with favorable histology disease, despite occasionally foreboding preoperative imaging [44 ] . Complications were minimal and long-term renal function and survival have been excellent. Definitive operative intervention should be done early, by 12 weeks after initiation of chemotherapy, as little significant further change in tumor size is likely [45] and it is important to determine the exact tumor histology [39, 46] . The finding of either anaplastic or blastemal predominant histology would mandate intensification of therapy if not Stage I disease, whereas certain other circumstances would allow for discontinuation of doxorubicin.
Intravascular tumor extension
Vena cava and intra-atrial extension of Wilms' tumor can occur in patients with Wilms' tumor, with an incidence of approximately 5%. Survival does not appear to be affected and the prognosis is comparable stage by stage with survival in children without intravascular involvement. Localization of the thrombus should be determined prior to operation utilizing real-time ultrasonography or echocardiography; sometimes MRI scanning can provide additional information. Surgical excision of the primary tumor and thrombus is recommended when technically feasible. An intra-abdominal approach is sufficient for infrahepatic lesions with extraction of the caval thrombus after proximal and distal control of the vena cava are obtained. Free-floating thrombi that are easily removed are classified as Stage II, but those that invade the vessel or are extremely adherent to the wall of the vessel are classified as Stage III. Patients with atrial extension of a tumor thrombus require cardiopulmonary bypass for thrombus removal. In these patients, a midline abdominal incision with a median sternotomy can be used. Alternatively, strong consideration should be given to the use of preoperative chemotherapy [47] [48] [49] [50] .
Metastatic disease
The primary distant site for Wilms' tumor metastases is the lungs; hepatic metastases are much less common. Approximately 12% of Wilms' tumor patients will have evidence of hematogenous metastases at diagnosis, with 80% having pulmonary metastases. Patients with Stage IV favorable histology tumors at diagnosis still have a good prognosis, whereas unfavorable histology patients and those who relapse with metastatic disease have a grave prognosis. Approximately 20% of favorable histology patients will relapse following therapy with a majority of relapses being in the lungs. Patients with pulmonary metastases usually can be managed by combined chemotherapy and radiation therapy [51] ; pulmonary resection is rarely indicated because chemotherapy is extremely effective. Although histologic confirmation of pulmonary relapse may be indicated, complete removal of pulmonary metastases at relapse does not increase survival.
A new response-based approach is now being taken for patients with Stage IV disease in AREN0533. Patients who are treated with regimen DD-4A and have complete radiographic disappearance of their lung metastases (or who have tissue confirmation that residual nodules do not contain viable tumor) at the week 6 re-evaluation will be considered 'rapid responders', will continue on DD-4A and will not receive pulmonary irradiation. Patients who do not have complete resolution of pulmonary nodules will be considered 'slow, incomplete responders', will be switched to regimen M and will receive whole lung irradiation. Those patients who have pulmonary metastases confirmed histologically at the time of diagnosis and have the lesions completely resected (and therefore have no residual disease available for response monitoring) will be treated with DD-4A but will also be required to receive whole lung irradiation. Therefore, consideration must be given to the implications of resecting pulmonary lesions at the time of diagnosis. If the lesions are found to be benign, the patient will have been spared doxorubicin (if local Stages I-II) and pulmonary irradiation. However, if the lesions are metastatic Wilms' tumor and are removed completely, the patient will have lost the opportunity to be considered a rapid responder and avoid whole lung irradiation.
Conclusion
Significant improvement has been made in the treatment of children with Wilms' tumor. New protocols in place are designed to maintain a high rate of cure for these patients while minimizing toxicity, based on the refinement of the risk stratification system. Surgeons play a critical role in the management of children with Wilms' tumor and it is imperative that they understand the directives of these new protocols and how the conduct of an operation can influence therapy and outcome for these patients.
